UC and CD represent the two major forms of inflammatory bowel disease (IBD: OMIM \#266600), which together affect approximately 1:250 people in Europe, North America and Australasia. Clinical features, epidemiological data and genetic evidence suggest that UC and CD are related polygenic diseases. In contrast to CD, bowel inflammation in UC is limited to the colonic mucosa. While disease-related mortality is low, morbidity remains high and 10-20% of affected individuals will undergo colectomy. Though the precise etiology is unknown, the current hypothesis is a dysregulated mucosal immune response to commensal gut flora in genetically susceptible individuals^[@R1]^. Recent genome-wide and candidate-gene association studies have identified 18 UC susceptibility loci, including 7 that overlap with CD (e.g. *IL23* pathway genes, *NKX2-3* and *IL10*). Known UC specific loci (*HNF4A, CDH1* and *LAMB1*) have highlighted the role of defective barrier function in disease pathogenesis^[@R2]^.

The 18 confirmed UC loci explain approximately 11% of UC heritability (see [Online Methods](#SD2){ref-type="supplementary-material"}). To identify additional UC susceptibility loci and further elucidate disease pathogenesis, we combined data from six GWAS using genotype imputation and meta-analysis methodology (see [Online Methods](#SD2){ref-type="supplementary-material"}). The discovery panel consisted of 6,687 cases and 19,718 controls of European descent with data available for at least 1.1 million SNPs ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). A quantile-quantile plot of the meta-analysis test statistics showed a marked excess of significant associations in the tail of the distribution ([Supplementary Figure 1](#SD2){ref-type="supplementary-material"}). Although the majority (16/18) of previously confirmed UC loci are at a genome-wide significant level (P\<5×10^-8^), two just failed to meet this threshold in the meta-analysis -- 4q27^[@R3]^, and 22q13^[@R4]^ ([Table 1](#T1){ref-type="table"}), though we still consider these to be true risk loci given the strength of association in the initial studies (*P*=1.35×10^-10^ and *P*=4.21×10^−8^ respectively). Fifty loci with P\< 1×10^-5^ and not previously associated with UC were followed up by genotyping the most associated SNP from each locus in an independent panel of 9,628 UC cases and 12,917 population controls (see [Online Methods](#SD2){ref-type="supplementary-material"} and [Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Of these, 28 loci had evidence of association (P\<0.05) in the follow-up panel and attained genome-wide significance (P\<5×10^-8^) in the combined analysis of meta-analysis and follow-up cohorts ([Table 2](#T2){ref-type="table"} and [Supplementary Table 3](#SD2){ref-type="supplementary-material"}). In addition, although the locus on 1q32 failed follow-up genotyping (rs7554511) it had been previously tested for association to UC in an independent cohort (rs11584383: P = 1.2×10^-5^)^[@R5]^. This alternative tag SNP achieves genome-wide significancein our current meta-analysis (P=3.7×10^-11^) and therefore we consider this a confirmed UC locus, bringing the total number of new UC loci to 29. It should be noted that 12 of the 29 loci had documented nominal evidence of association (5×10^-8^\<P\<0.05) to UC in previous reports (1p36^[@R2]^, 1q32^[@R6]^, 5q33^[@R6]^, 6p21^[@R5]^, 7q32^[@R7]^, 9p24^[@R5],[@R8]^, 9q34^[@R5],[@R9]^, 10p11^[@R6]^, 11q23^[@R5]^, 13q12^[@R8]^, 13q13^[@R2]^ and 20q13^[@R10]^). We also tested the 28 loci with follow-up genotype data for association with two clinically relevant disease sub-phenotypes (maximum disease extent and need for colectomy for medically refractory disease) but no significant associations were seen following correction for multiple testing (P\<5.2×10^-4^) ([Supplementary Table 4](#SD2){ref-type="supplementary-material"}). In summary, there are 47 confirmed UC susceptibility loci, 18 from previous studies and 29 from the current study.

As a first step towards obtaining biological insight from the identification of these 47 loci, we examined the gene content of the associated regions ([Supplementary Figure 2](#SD2){ref-type="supplementary-material"}). Although three regions contained a single gene (5p15:*DAP*, 6q21:*PRDM1*, 10q24:*NKX2-3*), most (35/47) contain multiple genes and nine are not believed to contain any gene ([Table 1](#T1){ref-type="table"}). We attempted to identify plausible candidate genes by (a) using a literature-mining tool (GRAIL) to identify non-random, evidence-based links between genes, (b) searching an existing eQTL database^[@R11]^ for correlations with our most associated SNPs ([Supplementary Table 5](#SD2){ref-type="supplementary-material"}), (c) using 1000 genomes data to identify non-synonymous SNPs in linkage disequilibrium (LD) (r^2^\>0.5) with the most associated SNP in the locus ([Supplementary Table 6](#SD2){ref-type="supplementary-material"}), and (d) determining the gene in closest physical proximity to the most associated SNP (see [Online Methods](#SD2){ref-type="supplementary-material"}). These approaches (results summarized in [Table 1](#T1){ref-type="table"}, [Table 2](#T2){ref-type="table"} and [Supplementary Table 7](#SD2){ref-type="supplementary-material"}) consistently identified a single candidate gene in six of the associated regions (2q11:*IL1R2*, 5p15:*IL7R*, 7p22:*GNA12*, 10p11:*CCNY*, 1p31:*IL23R*, 16q22:*ZFP90*), potentially prioritizing which genes to follow up in future genetic and functional studies. Noteworthy candidate genes are described in [Box 1](#BX1){ref-type="boxed-text"}. Follow-up genotyping in even larger independent panels of cases and controls from a range of ethnicities may be needed to identify the genes containing causal variants.

###### BOX 1 -- Candidate genes within associated loci

***TNFRSF14 / MMEL1* (1p36)**. *TNFRSF14* encodes a member of the TNF receptor superfamily. In a T cell transfer model of colitis, *TNFRSF14* expression by innate immune cells has an important role in preventing intestinal inflammation^[@R22]^. *MMEL1* encodes membrane metalloendopeptidase-like 1. This locus is associated with susceptibility to celiac disease and primary biliary cirrhosis; a nsSNP in MMEL1 was nominally associated with multiple sclerosis.

***TNFRSF9* (1p36)**: Tumour necrosis factor receptor superfamily member 9 is involved as a co-stimulator in the regulation of peripheral T cell activation, with enhanced proliferation and IL2 secretion. It is expressed by dendritic cells, granulocytes and endothelial cells at sites of inflammation. SCID mice transferred with naive CD4+ T cells from TNFRFSF9-deficient mice develop colitis of equal intensity as SCID mice transferred with wild type naïve T cells, but with amodified cytokine response^[@R23]^.

***IL1R2* (2q11)**: Interleukin 1 receptor, type II binds IL1a, IL1b and IL1R1, inhibiting the activity of these ligands. Two alternative splice transcripts of *IL1R2* have been reported. This protein serves to antagonise the action of IL1a and IL1b, pleiotropic cytokines with various roles in inflammatory processes. IL1b production by lamina propria macrophages is increased in patients with UC^[@R24]^.

This locus is immediately adjacent to a CD-associated locus containing *IL18RAP, ILR1* and other genes. It is unclear at present whether the CD-associated and UC-associated SNPs in these regions tag two separate loci or one locus. The lead CD SNP has a P=0.001 in our UC meta-analysis. There is a large recombination hotspot between *IL1R2* (UC) and *IL1R1* (CD).

***IL8RA / IL8RB* (2q35)**: *IL8RA* and *IL8RB* encode two receptors for interleukin-8, a powerful neutrophil chemotactic factor. *IL8RA* expression, limited to a subpopulation of lamina propria macrophages and germinal centre lymphocytes in the healthy colon, is increased in macrophages, lymphocytes and epithelium in UC^[@R25]^. *IL8RB* expression is more limited and not upregulated in UC. *IL8* expression is profoundly increased in colonic tissue from UC patients compared with controls; this increase is driven by inflammation^[@R26]^.

***DAP* (5p15)** encodes death-associated protein. The DAPs are a heterogenous group of polypeptides isolated in a screen for elements involved in the IFNγ -- induced apoptosis of HeLa cells. *DAP* negatively regulates autophagy and is a substrate of mTOR^[@R13]^.

***IL7R* (5p13)** encodes the receptor for interleukin-7. IL7 is a key regulator of naïve and memory T cell survival, specifically the transition from effector to memory T cells^[@R27]^. T cells expressing high levels of IL7R are seen in human and murine colitis; selective depletion of these cells ameliorates established colitis ^[@R28]^. *IL7R* is a confirmed multiple sclerosis susceptibility gene^[@R29]^. The gene may have undergone extensive evolutionary selective pressure by intestinal helminths^[@R30]^.

***PRDM1* (6q21)** encodes PR domain containing 1, with ZNF domain (synonym BLIMP1), the master transcriptional regulator of plasma cells and a transcriptional repressor of the IFN-β promoter. It plays important roles in the proliferation, survival and differentiation of B and T lymphocytes.

***GNA12* (7p22)** encodes guanine nucleotide binding protein (G protein) alpha 12, a membrane bound GTPase that plays an important role in tight junction assembly in epithelial cells, through interactions with ZO-1 and Src^[@R20]^.

***IRF5 (7q32)*** encoding interferon regulatory factor 5, is a confirmed susceptibility gene for rheumatoid arthritis, SLE and primary biliary cirrhosis. This transcription factor regulates activity of type I interferons and induces cytokines including IL-6, IL-12 and TNFα, via TLR signaling. In response to mycobacterium tuberculosis infection of macrophages, Type I interferon expression is dependent on a pathway including *IRF5, NOD2* and *RIP2*^[@R31]^.

***LSP1* (11q15)**: Lymphocyte-specific protein-1 is expressed by lymphocytes and macrophages, and also in endothelium wherein it is critical for normal neutrophil transmigration^[@R32]^.

Additional bioinformatic analyses were also performed on the entire set of genes in the associated regions to search for functional commonalities across this large number of loci (see [Online Methods](#SD2){ref-type="supplementary-material"}). Specifically, using a gene set enrichment approach the UC loci are seen to have more genes associated with cytokines and cytokine receptors (including IFNγ, several interleukins, five TNF and TNFR superfamily members), key regulators of cytokine-mediated signaling pathways, innate and adaptive immune response, macrophage activation and regulation of apoptosis than would be expected by chance ([Supplementary Table 8 and Supplementary Figure 3](#SD2){ref-type="supplementary-material"}). Enrichment analysis of the subset of candidate loci with no known association to other inflammatory diseases showed significant over-representation of gene sets associated with MAP kinase signaling, actin binding, calcium-dependent processes, fatty acid and lipid metabolism ([Supplementary Table 8 and Supplementary Figure 3](#SD2){ref-type="supplementary-material"}).

The 5p15 locus contains a single gene, *DAP* (death-associated protein), with the most associated SNP in this region having a strong eQTL effect on *DAP* expression (P=2.59×10^-12^)^[@R11]^. DAP kinase expression has been shown to increase with inflammation in UC^[@R12]^, and DAP itself has recently been identified as a novel substrate of mTOR (mammalian target of rapamycin)^[@R13]^ and as a negative regulator of autophagy. While autophagic processes have previously been implicated in CD due to associations with *ATG16L1* and *IRGM*^[@R14]^, this association with *DAP* suggests a possible link between autophagy and UC.

Association to loci containing *PRDM1, IRF5* and *NKX2-3* suggests an important role for transcriptional regulation in UC pathogenesis. A key example is BLIMP-1, encoded by the *PRDM1* gene, whose most important function is in B cells, as the master transcriptional regulator of plasma cells^[@R15]^. It also functions in T cells to attenuate IL-2 production upon antigen stimulation^[@R16]^, and topromote the development of short-lived effector cells and regulate clonal exhaustion in both CD4 and CD8 cells^[@R17]^. It is noteworthy that the 11q24 celiac disease susceptibility locus containing ETS1, a transcription factor essential for T-bet induced production of *IFNγ* and the development of colitis in animal models, just fails to reach genome-wide significance in our study (P=1.22×10^-7^, [Supplementary Table 3b](#SD2){ref-type="supplementary-material"})^[@R18],[@R19]^.

Identification of *GNA12* as the most likely candidate at the 7p22 locus suggests a role for intestinal barrier function as this gene is implicated in tight junction assembly in epithelial cells^[@R20]^. Barrier integrity appears to be a key pathway in UC pathogenesis given previous associations to loci containing *HNF4A, CDH1* and *LAMB1*^[@R2],[@R5]^.

Given the phenotypic overlap between UC and CD, we examined the evidence for association at all 47 UC loci in our recently completed CD GWAS meta-analysis comprising 6,333 cases and 15,056 controls^[@R14]^ and, conversely, for evidence of association at all confirmed CD loci in our UC meta-analysis ([Table 3](#T3){ref-type="table"} and [Supplementary Table 9](#SD2){ref-type="supplementary-material"}). We find that, among the 99 confirmed IBD loci meeting genome-wide significance (P\<5×10^-8^) either in UC and/or CD, 28 independent index SNPs have P\<1×10^-4^ in both scans. Interestingly, all index SNPs meeting these criteria showed the same direction of effect in both diseases, thus pointing to a minimum of 28 shared association signals between UC and CD. Multiple genes involved in the IL23 signaling pathway are included in this overlapping SNP list, specifically *IL23R, JAK2, STAT3, IL12B (p40)*, and *PTPN2*. The significance of these findings is underlined by the central role played by *IL23* in the induction of *IL17* by Th17 lymphocytes, its established role in other autoimmune disorders, and the intense interest in therapeutic manipulation of the *IL23-IL23R* interaction through blockade of the p40 or p19 IL23 subunits.

Loci not meeting these inclusion criteria cannot be formally discounted as shared loci, indeed many of the confirmed UC/CD loci with nominal association (1×10^-4^\<P\<0.05) to the other disease may be shared. Among the confirmed UC loci with no evidence (P\>0.05) of association to CD are the three containing candidate genes that play a role in intestinal barrier function (*GNA12, HNF4A*, and *LAMB1*).

In addition to loci shared with CD, 19 of the 47 UC risk loci are also associated with other immune-mediated diseases ([Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}). In particular, these "shared loci" are enriched for genes involved in T-cell differentiation, specifically in the differentiation of T~H~1 and T~H~17 cells (e.g. loci encoding *IL23R, IL21, IL10, IL7R, IFNG*). Dysregulated auto-antigen specific T~H~1 responses are believed to be involved in organ-specific autoimmune diseases, and T~H~17 cells are increasingly recognized to contribute to host defense and induction of autoimmunity and tissue inflammation^[@R21]^. Another shared pathway between UC and other immune mediated diseases involves TNF-signaling (*TNFRSF9, TNFRSF14, TNFSF15*) with widespread immunological effects including NF-κB activation, a known key component of the inflammatory response in IBD.

The current study has more than doubled the number of confirmed UC susceptibility loci and we estimate that 16% of UC heritability is explained by these loci (see [Online Methods](#SD2){ref-type="supplementary-material"}). We have identified potentially causal genes at several loci but confirmation of causality awaits detailed fine-mapping, expression and functional studies. Dense fine-mapping and large-scale re-sequencing studies are underway with the goal of identifying the causal variation within many of these loci.
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###### Association results and *in silico* analyses for the 18 previously confirmed (P\<5×10^-8^) ulcerative colitis (UC) loci

Left-right association boundaries are given for each index SNP (see [Online Methods](#SD2){ref-type="supplementary-material"}). RAF = risk allele frequency. OR is estimated using the meta-analysis cohort only. Known associations represent phenotypes previously associated with the locus at P\<5×10^-8^). AS = ankylosing spondylitis, Ast = Asthma, BD = Behçet's disease, CD = Crohn's disease, CeD = celiac disease, Graves' disease = GD, HL = Hodgkin's lymphoma, MS = multiple sclerosis, PBC = primary biliary sclerosis, Ps = psoriasis, RA = rheumatoid arthritis, SLE = systemic lupus erythematosus, T1D = type 1 diabetes and WBC = white blood cell count. Candidate genes of interest are listed. Those in bold were highlighted by *in silico* analyses (GRAIL connectivity and/or presence of an eQTL or nonsynonymous SNP. See [Online Methods and Supplementary Table 7](#SD2){ref-type="supplementary-material"} for more details).

  dbSNP ID     Chr.    Left-right(Mb)   Risk Allele   Allele frequency in controls   P-value (meta)   OR (95% CI)        Association reported with other phenotypes   Positional candidate genes of interest
  ------------ ------- ---------------- ------------- ------------------------------ ---------------- ------------------ -------------------------------------------- ----------------------------------------------------
  rs6426833    1p36    19.93-20.18      A             0.541                          3.93 × 10^-35^   1.30 (1.25-1.35)                                                
  rs11209026   1p31    67.30-67.54      G             0.935                          5.12 × 10^-28^   1.74 (1.57-1.92)   CD, AS, BD, Ps                               ***IL23R***
  rs1801274    1q23    159.54-159.91    A             0.505                          2.16 × 10^-20^   1.21 (1.16-1.26)   SLE                                          ***FCGR2A, FCGR2B, HSPA6***
  rs3024505    1q32    204.85-205.11    A             0.159                          5.76 × 10^-17^   1.25 (1.19-1.32)   CD, BD, SLE, T1D                             ***IL10, IL19***
  rs7608910    2p16    60.76-61.87      G             0.390                          1.70 × 10^-14^   1.19 (1.14-1.24)   CD, CeD, RA                                  *PUS10*
  rs4676406    2q37    241.20-241.32    T             0.516                          8.32 × 10^-11^   1.14 (1.09-1.18)                                                ***GPR35***
  rs9822268    3p21    48.14-51.77      A             0.302                          1.60 × 10^-17^   1.21 (1.16-1.26)   CD                                           **MST1, *UBA7, APEH, AMIGO3, GMPPB, BSN***
  rs17388568   4q27    123.20-123.78    A             0.273                          9.49 × 10^-7^    1.12 (1.07-1.17)   CeD, T1D                                     ***IL21, IL2**, ADAD1*
  rs11739663   5p15    0.48-0.80        T             0.767                          2.80 × 10^-8^    1.15 (1.09-1.21)                                                ***EXOC3***
  rs9268853    6p21    31.49-33.01      T             0.661                          1.35 × 10^-55^   1.40 (1.34-1.47)   CD, CeD, GrD, MS, PBC, RA, T1D               ***HLA-DRB5, HLA-DQA1, HLA-DRB1, HLA-DRA, BTNL2***
  rs4510766    7q22    107.20-107.39    A             0.559                          2.00 × 10^-16^   1.20 (1.15-1.26)                                                
  rs6584283    10q24   101.25-101.33    T             0.472                          8.46 × 10^-21^   1.21 (1.16-1.26)   CD                                           
  rs7134599    12q14   66.72-66.92      A             0.385                          1.06 × 10^-16^   1.19 (1.14-1.24)                                                ***IFNG, IL26***
  rs6499188    16q22   66.98-67.40      A             0.749                          3.97 × 10^-8^    1.14 (1.09-1.20)                                                ***ZFP90***
  rs2872507    17q12   34.62-35.51      A             0.463                          5.44 × 10^-11^   1.15 (1.10-1.19)   CD, Ast, PBC, T1D, WBC                       ***IKZF3, ORMDL3, IKZF3, PNMT*, ZPBP2, GSDML**
  rs6017342    20q13   42.49-42.70      C             0.538                          1.09 × 10^-20^   1.20 (1.15-1.26)   HDL                                          ***SERINC3***
  rs2836878    21q22   39.34-39.41      G             0.738                          1.86 × 10^-22^   1.25 (1.20-1.32)   AS                                           
  rs5771069    22q13   48.70-48.83      G             0.515                          1.87 × 10^-7^    1.11 (1.07-1.16)                                                ***PIM3, IL17REL***

###### Association results and *in silico* analyses for the 29 newly confirmed ulcerative colitis (UC) loci

UC loci that meet genome-wide significance P\<5×10^-8^ in the combined analysis and P\<0.05 in the replication study. Left-right association boundaries are given for each index SNP (see [Online Methods](#SD2){ref-type="supplementary-material"}). RAF = risk allele frequency. OR is estimated using the replication cohort only. Known associations represent phenotypes previously associated with the locus at P\<5×10^-8^. AtD = atopic dermatitis, BMD = bone mineral density, CD = Crohn's disease, CeD = celiac disease, Gli = glioma, Lep = leprosy, MS = multiple sclerosis, MyN = myeloproliferative neoplasms, PBC = primary biliary sclerosis, Ps = psoriasis, RA = rheumatoid arthritis and SLE = systemic lupus erythematosus. Candidate genes of interest are listed. Those in bold were highlighted by *in silico* analyses (GRAIL connectivity and/or presence of an eQTL or nonsynonymous SNP. See [Online Methods and Supplementary Table 7](#SD2){ref-type="supplementary-material"} for more details).

  dbSNP ID      Chr.    Left-right(Mb)   Risk Allele   Allele frequency in controls   P-value (meta)   P-value (follow-up)   P-value (comb)   OR (95% CI)        Association reported with other phenotypes   Positional candidate genes of interest
  ------------- ------- ---------------- ------------- ------------------------------ ---------------- --------------------- ---------------- ------------------ -------------------------------------------- -------------------------------------------------------
  rs734999      1p36    2.39-2.80        C             0.524                          1.21 × 10^-9^    1.51 × 10^-2^         3.34 × 10^-9^    1.05 (1.01-1.09)   CeD, PBC                                     ***TNFRSF14, MMEL1, PLCH2, C1orf93***
  rs35675666    1p36    7.83-8.13        G             0.829                          1.09 × 10^-8^    1.13 × 10^-2^         4.84 × 10^-9^    1.08 (1.02-1.15)   CD                                           ***TNFRSF9, ERFFI1,UTS2**,PARK7*
  rs7524102     1p36    22.54-22.61      A             0.828                          1.04 × 10^-11^   2.06 × 10^-4^         1.65 × 10^-13^   1.10 (1.05-1.16)   BMD                                          
  rs7554511     1q32    199.06-199.33    C             0.721                          2.04 × 10^-13^   NA                    NA               1.19 (1.14-1.25)   CD, CeD                                      *C1orf106*
  rs2310173     2q11    101.66-102.13    T             0.461                          8.44 × 10^-8^    5.94 × 10^-6^         3.17 × 10^-12^   1.09 (1.05-1.14)                                                ***IL1R2***
  rs11676348    2q35    218.58-218.97    T             0.486                          8.78 × 10^-9^    6.18 × 10^-4^         1.25 × 10^-10^   1.07 (1.03-1.11)                                                ***IL8RA, SLC11A1, IL8RB, AAMP, ARPC***
  rs267939      5p15    10.72-10.90      C             0.368                          9.67 × 10^-7^    1.27 × 10^-6^         6.01 × 10^-12^   1.10 (1.06-1.15)                                                ***DAP***
  rs3194051     5p13    35.83-36.07      G             0.269                          2.19 × 10^-6^    2.06 × 10^-3^         4.22 × 10^-8^    1.07 (1.02-1.12)   MS                                           ***IL7R***
  rs6451493\*   5p13    40.32-40.85      T             0.610                          1.78 × 10^-6^    2.09 × 10^-4^         2.80 × 10^-9^    1.08 (1.04-1.12)   CD, MS                                       ***PTGER4***
  rs254560      5q31    134.41-134.53    A             0.397                          3.06 × 10^-7^    4.19 × 10^-4^         1.25 × 10^-9^    1.07 (1.03-1.12)                                                
  rs6871626     5q33    158.46-158.86    A             0.334                          1.02 × 10^-8^    1.40 × 10^-14^        1.11 × 10^-21^   1.17 (1.12-1.22)   CD, Ps, SLE                                  ***IL12B***
  rs943072      6p21    43.88-43.92      G             0.092                          1.05 × 10^-6^    3.71 × 10^-5^         2.37 × 10^-10^   1.15 (1.08-1.23)                                                
  rs6911490     6q21    106.51-106.67    T             0.210                          3.51 × 10^-7^    1.70 × 10^-3^         1.01 × 10^-8^    1.08 (1.03-1.13)   CD, RA, SLE                                  ***PDRM1***
  rs6920220     6q23    137.88-138.17    A             0.207                          6.38 × 10^-10^   1.94 × 10^-8^         8.05 × 10^-17^   1.14 (1.09-1.20)   CeD, Ps, RA, SLE                             
  rs798502      7p22    2.70-2.90        A             0.711                          1.21 × 10^-8^    3.82 × 10^-8^         2.61 × 10^-15^   1.13 (1.08-1.18)                                                ***GNA12***
  rs4728142     7q32    128.33-128.56    A             0.444                          1.68 × 10^-6^    1.25 × 10^-3^         1.74 × 10^-8^    1.07 (1.03-1.11)   SLE, RA, PBC                                 ***IRF5, TNPO3***
  rs10758669    9p24    4.93-5.28        C             0.350                          8.52 × 10^-13^   3.78 × 10^-14^        2.22 × 10^-25^   1.17 (1.12-1.21)   CD, MyN                                      ***JAK2***
  rs4246905     9q32    116.48-116.74    C             0.713                          4.77 × 10^-8^    1.44 × 10^-5^         5.65 × 10^-12^   1.10 (1.05-1.15)   CD, Lep                                      ***TNFSF8, TNFSF15***
  rs10781499    9q34    138.27-138.55    A             0.411                          6.95 × 10^-13^   2.50 × 10^-8^         2.62 × 10^-19^   1.12 (1.08-1.17)   CD                                           ***CARD9, INPP5E, SDCCAG3, SEC16A, SNAPC4***
  rs12261843    10p11   35.22-35.94      G             0.286                          2.35 × 10^-8^    1.22 × 10^-3^         7.09 × 10^-10^   1.07 (1.03-1.12)   CD                                           ***CCNY***
  rs907611      11q15   1.82-1.93        A             0.317                          2.49 × 10^-8^    3.58 × 10^-4^         1.38 × 10^-10^   1.08 (1.03-1.13)                                                ***LSP1***
  rs2155219     11q13   75.72-76.02      T             0.500                          6.33 × 10^-8^    1.61 × 10^-9^         5.39 × 10^-16^   1.13 (1.08-1.17)   CD, AtD                                      
  rs678170      11q23   113.76-114.08    A             0.661                          6.88 × 10^-11^   2.50 × 10^-5^         4.65 × 10^-14^   1.09 (1.05-1.14)                                                
  rs17085007    13q12   26.39-26.46      C             0.178                          3.30 × 10^-9^    4.66 × 10^-9^         9.65 × 10^-17^   1.16 (1.10-1.21)                                                
  rs941823      13q13   39.90-39.95      C             0.756                          3.93 × 10^-7^    1.93 × 10^-6^         3.82 × 10^-12^   1.12 (1.07-1.17)                                                
  rs16940202    16q24   84.53-84.58      C             0.180                          1.27 × 10^-12^   1.42 × 10^-8^         5.96 × 10^-19^   1.15 (1.10-1.21)   MS                                           
  rs2297441     20q13   61.66-61.98      A             0.766                          5.78 × 10^-8^    2.68 × 10^-4^         1.70 × 10^-10^   1.09 (1.04-1.15)   CD, Gli                                      ***SLC2A4RG, STMN3, ZBTB46, ZGPAT, RTEL1, TNFRSF6B***
  rs1297265     21q21   15.62-15.77      A             0.564                          1.73 × 10^-7^    5.02 × 10^-7^         6.99 × 10^-13^   1.11 (1.06-1.15)   CD                                           
  rs2838519     21q22   44.41-44.52      G             0.390                          2.26 × 10^-8^    7.10 × 10^-4^         6.41 × 10^-11^   1.14 (1.05-1.22)   CD                                           ***ICOSLG***

###### Shared association signals between UC and CD

A shared association is defined as a confirmed association (P~combined~ \< 5×10^-8^) in either UC or CD and P~meta~ \< 1×10-4 in the other form of IBD. For more details and comparative results across all 99 reported IBD risk loci see [Supplementary table 9](#SD2){ref-type="supplementary-material"}.

  LOCUS   GENE            INDEX SNP          CD-META (6333/15056)    UC-META (6687/19718)                                                           
  ------- --------------- ------------------ ----------------------- ---------------------- ------ -------------- ------------------ -------------- ------------------
  1p31    67.30-67.54     *IL23R*            rs11209026              G                      0.94   1.00×10^-64^   2.67 (2.37-3.01)   5.12×10^-28^   1.74 (1.57-1.92)
                                                                                                                                                    
  1q32    199.0 -199.33   *KIF21B*           rs7554511               C                      0.72   1.58×10^-7^    1.14 (1.08-1.19)   2.04×10^-13^   1.19 (1.14-1.25)
                                                                                                                                                    
  1q32    204.85-205.11   *IL10*             rs3024505               A                      0.16   8.32×10^-9^    1.18 (1.12-1.25)   5.76×10^-17^   1.25 (1.19-1.32)
                                                                                                                                                    
  2p16    60.76-61.87     *REL*              rs7608910               G                      0.39   3.11×10^-7^    1.14 (1.09-1.21)   1.70×10^-14^   1.19 (1.14-1.24)
                                                                                                                                                    
  2q11    101.66-102.13   *IL1R2*            rs2310173               T                      0.46   8.31×10^-5^    1.09 (1.04-1.14)   8.44×10^-8^    1.12 (1.07-1.16)
                                                                                                                                                    
  3p21    48.14-51.77     *MST1*             rs3197999               A                      0.30   6.17×10^-17^   1.22 (1.16-1.27)   1.86×10^-17^   1.21 (1.16-1.26)
                                                                                                                                                    
  5p13    40.32-40.85     *PTGER4*           rs6451493               T                      0.61   1.61×10^-27^   1.35 (1.28-1.43)   1.78×10^-6^    1.12 (1.07-1.17)
                                                                                                                                                    
                          *IL12B*            rs6871626               A                      0.33   6.08×10^-12^   1.15 (1.10-1.20)   1.02×10^-8^    1.12 (1.08-1.17)
  5q33    158.46-158.86   *IL12B*            rs6556412 (r^2^=0.03)   A                      0.34   5.37×10^-14^   1.18 (1.13-1.23)   1.69×10^-5^    1.09 (1.05-1.14)
                                                                                                                                                    
  6p22    20.60-21.25     *CDKAL1*           rs6908425               C                      0.78   1.41×10^-8^    1.17 (1.11-1.23)   7.75×10^-5^    1.11 (1.05-1.16)
                                                                                                                                                    
  6q21    106.51-106.67   *PRDM1*            rs6911490               T                      0.21   4.28×10^-7^    1.12 (1.07-1.18)   3.51×10^-7^    1.13 (1.07-1.18)
                                                                                                                                                    
  9p24    4.93-5.29       *JAK2*             rs10758669              C                      0.35   1.00×10^-13^   1.18 (1.13-1.23)   8.52×10^-13^   1.16 (1.11-1.21)
                                                                                                                                                    
  9q32    116.48-116.74   *TNFSF15*          rs4246905               C                      0.71   1.33×10^-15^   1.21 (1.15-1.28)   4.77×10^-8^    1.13 (1.08-1.18)
                                                                                                                                                    
  9q34    138.27-138.55   *CARD9*            rs10781499              A                      0.40   3.49×10^-18^   1.20 (1.15-1.26)   6.95×10^-13^   1.16 (1.11-1.21)
                                                                                                                                                    
  10p11   35.22-35.94     *CREM/CCNY*        rs12261843              G                      0.29   1.87×10^-9^    1.15 (1.10-1.20)   2.35×10^-8^    1.13 (1.08-1.18)
                                                                                                                                                    
  10q21   63.97-64.43     *ZNF365*           rs10761659              G                      0.54   4.37×10^-22^   1.23 (1.18-1.28)   7.39×10^-6^    1.10 (1.05-1.14)
                                                                                                                                                    
  10q24   101.25-101.33   *NKX2.3*           rs6584283               T                      0.47   7.18×10^-20^   1.21 (1.16-1.27)   8.46×10^-21^   1.21 (1.16-1.26)
                                                                                                                                                    
  11q13   75.72-76.02     *C11Orf30*         rs2155219               T                      0.50   1.58×10^-12^   1.16 (1.11-1.21)   6.33×10^-8^    1.12 (1.07-1.16)
                                                                                                                                                    
  15q22   65.2-65.27      *SMAD3*            rs17293632              T                      0.24   1.41×10^-13^   1.19 (1.14-1.25)   9.52×10^-6^    1.11 (1.06-1.16)
                                                                                                                                                    
  17q12   34.62-35.51     *ORMDL3*           rs2872507               A                      0.46   1.51×10^-9^    1.14 (1.09-1.19)   5.44×10^-11^   1.15 (1.10-1.19)
                                                                                                                                                    
  18p11   12.73-12.92     *PTPN2*            rs1893217               G                      0.16   1.29×10^-14^   1.25 (1.18-1.32)   4.78×10^-5^    1.12 (1.06-1.18)
                                                                                                                                                    
  19p13   10.26-10.5      *TYK2*             rs12720356              C                      0.08   9.20×10^-10^   1.22 (1.14-1.31)   3.90×10^-6^    1.17 (1.09-1.26)
                                                                                                                                                    
  19q13   38.42-38.47     \-                 rs736289                T                      0.61   2.69×10^-7^    1.11 (1.06-1.16)   1.89×10^-5^    1.08 (1.03-1.12)
                                                                                                                                                    
  20q13   61.66-61.98     *RTEL1/SLC2A4RG*   rs2297441               A                      0.76   1.83×10^-11^   1.19 (1.13-1.25)   5.78×10^-8^    1.14 (1.09-1.20)
                                                                                                                                                    
  21q21   15.62-15.77     \-                 rs1297265               A                      0.57   1.41×10^-8^    1.16 (1.10-1.22)   1.73×10^-7^    1.11 (1.06-1.16)
                                                                                                                                                    
  21q22   39.34-39.41     \-                 rs2836878               G                      0.74   3.22×10^-6^    1.12 (1.06-1.17)   1.86×10^-22^   1.25 (1.20-1.32)
                                                                                                                                                    
  21q22   44.41-44.52     *ICOSLG*           rs2838519               G                      0.39   2.09×10^-14^   1.18 (1.13-1.23)   2.26×10^-8^    1.12 (1.08-1.17)
                                                                                                                                                    
  22q11   20.14-20.39     *YDJC*             rs181359                A                      0.19   6.31×10^-13^   1.21 (1.15-1.28)   2.73×10^-5^    1.11 (1.06-1.17)
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